Per Falk

Per joined Ferring Pharmaceuticals in 2015 and was appointed President from January 1st 2019. He also holds the role of Chief Science Officer, with responsibility for overseeing Ferring’s Research, Development & Regulatory activities.

Prior to joining Ferring, Per held executive and senior leadership positions at Novo Nordisk and AstraZeneca in research, medical and clinical development roles.

For over 30 years, Per has been investigating and evolving microbiome science, holding faculty positions at some of the world’s leading institutions to advance research in this field. During his career, he has held the role of Associate Professor at the Karolinska Institute, Sweden and the Washington University School of Medicine, USA.

Per is a qualified medical doctor and also has a Ph.D. in Biochemistry and Clinical Chemistry.